GO:0010717 regulation of epithelial to mesenchymal transition: Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0010717 describes any process that modulates the rate, frequency, or extent of epithelial to mesenchymal transition (EMT), a program in which epithelial cells lose apical-basolateral polarity, dissolve intercellular junctions, degrade basement membrane and become migratory mesenchymal cells.
• EMT is not a single switch but a spectrum that includes hybrid E/M states, which are frequently observed in cancer progression and metastasis.
• Core EMT transcription factors such as SNAI1, SNAI2, TWIST1, ZEB1 and ZEB2 repress epithelial genes and activate mesenchymal programs.
• Regulation of EMT is layered: epigenetic modifiers (for example LSD1/KDM1A), hypoxia signaling through HIF-1alpha, and DNA repair proteins such as BRCA1 all modulate EMT.
• Dysregulated EMT regulation contributes to cancer invasion, metastasis, chemoresistance, and to trophoblast-related pregnancy disorders.
• CRISPR-based knockout, point mutation, knock-in and overexpression models allow causal testing of EMT regulators in isogenic cell backgrounds.
Description
Epithelial to mesenchymal transition (EMT) is a fundamental developmental and pathological process in which polarized epithelial cells acquire a migratory mesenchymal phenotype. GO:0010717, regulation of epithelial to mesenchymal transition, captures all molecular events that modulate the rate, frequency, or extent of this transition, including transcriptional, epigenetic, and signaling inputs. Because EMT is reversible and context-dependent, its regulation is central to embryonic development, wound healing, fibrosis and cancer progression. Researchers study GO:0010717 to identify upstream regulators that could be targeted to block metastasis or to control tissue remodeling. The term is intentionally broad: it includes positive and negative regulators, such as EMT-inducing transcription factors and their repressors, as well as microenvironmental cues like hypoxia. Understanding this regulatory layer is essential because hybrid E/M states, rather than complete transitions, often drive aggressive tumor behavior. Consequently, GO:0010717 is a high-value annotation for functional genomics, drug target discovery and CRISPR screening.
regulation of epithelial to mesenchymal transition At A Glance
| GO ID | GO:0010717 |
|---|---|
| GO term | regulation of epithelial to mesenchymal transition |
| Ontology | biological_process |
| Synonym | none listed in QuickGO |
| Major function | Modulates the rate, frequency, or extent of EMT, a program of polarity loss, junction disassembly, basement membrane degradation and mesenchymal conversion |
| Key regulators | SNAI1, SNAI2, TWIST1, ZEB1, ZEB2, TGFB1, HIF1A, LSD1/KDM1A, BRCA1 |
| Disease relevance | Cancer metastasis, chemoresistance, fibrosis, trophoblast disorders |
| Research methods | CRISPR knockout/knock-in, RNA-seq, ChIP-seq, imaging, organoids |
What Is GO:0010717?
GO:0010717 is a biological process term defined as any process that modulates the rate, frequency, or extent of epithelial to mesenchymal transition. In this transition, an epithelial cell loses apical/basolateral polarity, severs intercellular adhesive junctions, degrades basement membrane components and becomes a migratory mesenchymal cell. The term therefore covers positive and negative regulation of EMT, including transcriptional control by EMT transcription factors, epigenetic remodeling, and signaling from the microenvironment.
Why Is regulation of epithelial to mesenchymal transition Important in Cell Biology?
Regulation of EMT (GO:0010717) is important because it controls a reversible cell-state transition that underlies normal development but also drives cancer invasion, metastasis and therapy resistance. The same regulatory nodes are implicated in trophoblast biology and pregnancy disorders, and in fibrotic remodeling of multiple organs. Because EMT is not binary, understanding its regulation helps explain why hybrid E/M cells are often the most aggressive. Targeting EMT regulators is therefore a major therapeutic strategy, and CRISPR models provide causal evidence for candidate regulators.
• Controls developmental EMT events such as gastrulation and neural crest delamination.
• Drives cancer cell invasion and metastatic dissemination in carcinomas and sarcomas such as osteosarcoma.
• Contributes to chemoresistance and immune evasion in tumors.
• Regulates trophoblast invasion and placental development; dysregulation is linked to pregnancy disorders.
• Is modulated by hypoxia through the HIF-1alpha network, linking microenvironment to EMT.
• Involves epigenetic enzymes such as LSD1/KDM1A that alter chromatin to sustain mesenchymal states.
• BRCA1 status influences EMT regulation in breast cancer, connecting DNA repair to cell plasticity.
• Hybrid E/M states, rather than complete EMT, correlate with stemness and poor prognosis.
• Provides a rich source of drug targets and biomarkers for anti-metastatic therapy.
• Enables functional genomics screens using CRISPR libraries to identify novel EMT regulators.
What Happens During regulation of epithelial to mesenchymal transition?
Initiation by EMT-inducing signals
In simple terms: Cells receive external signals that tell them to start changing identity.
EMT is initiated by extracellular cues such as TGF-beta, Wnt, Notch and hypoxia, which activate intracellular signaling cascades. These signals converge on EMT transcription factors including SNAI1, SNAI2, TWIST1, ZEB1 and ZEB2, which begin to repress epithelial genes. Hypoxia stabilizes HIF-1alpha, which directly or indirectly promotes EMT-associated gene expression. The initiation phase is reversible and often produces hybrid E/M states rather than a complete transition.
Transcriptional repression of epithelial identity
In simple terms: Master regulators switch off the genes that keep cells tightly glued together.
EMT transcription factors bind E-box elements in promoters of epithelial genes such as CDH1 (E-cadherin) and repress their transcription. SNAI1 and SNAI2 recruit co-repressors and epigenetic modifiers to silence epithelial loci. ZEB1 and ZEB2 also repress epithelial genes and can form double-negative feedback loops with microRNAs. This transcriptional reprogramming is a hallmark of EMT regulation and is frequently dysregulated in cancer.
Epigenetic remodeling during EMT
In simple terms: Chemical tags on DNA and histones lock in the new cell state.
Epigenetic enzymes such as LSD1/KDM1A remove activating histone marks and cooperate with EMT transcription factors to silence epithelial genes. DNA methylation and histone acetylation changes further stabilize the mesenchymal phenotype. In trophoblast biology, epigenetic regulation of EMT is critical for normal placental development and is disrupted in pregnancy disorders. These epigenetic layers make EMT regulation durable and potentially reversible with epigenetic drugs.
Cytoskeletal and junctional reorganization
In simple terms: The cell takes apart its glue and rebuilds its skeleton to move.
Regulated EMT involves loss of apical-basolateral polarity, disassembly of tight junctions and adherens junctions, and degradation of basement membrane components. Cytoskeletal changes, including actin stress fiber formation, enable migratory and invasive behavior. These morphological changes are driven by the transcriptional and epigenetic programs described above.
Hybrid E/M states and plasticity
In simple terms: Cells can get stuck halfway, and that halfway state is often the most dangerous.
Emerging concepts highlight hybrid epithelial/mesenchymal states in which cells co-express epithelial and mesenchymal markers. These hybrid states are associated with cancer stemness, collective migration and therapy resistance. Regulation of EMT therefore includes mechanisms that maintain or resolve hybrid states, such as microRNA feedback loops and microenvironmental signals. This plasticity explains why EMT is best viewed as a spectrum rather than a binary switch.
Key Genes Involved in GO:0010717 regulation of epithelial to mesenchymal transition
The following genes and proteins are established regulators or effectors of epithelial to mesenchymal transition (GO:0010717) and are frequently studied in cancer, developmental and trophoblast research.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SNAI1 | Transcriptional repressor of E-cadherin; EMT inducer | Core EMT transcription factor; target for knockout and overexpression studies |
| SNAI2 | Transcriptional repressor; promotes mesenchymal phenotype | Studied in cancer invasion and development |
| TWIST1 | bHLH transcription factor; promotes EMT and stemness | Linked to metastasis and chemoresistance |
| ZEB1 | Transcriptional repressor of epithelial genes | Key EMT regulator; feedback with miR-200 |
| ZEB2 | Transcriptional repressor; EMT inducer | Implicated in cancer progression and fibrosis |
| CDH1 | E-cadherin; maintains epithelial adhesion | Loss is a hallmark of EMT; frequently mutated in cancer |
| TGFB1 | Cytokine that induces EMT | Major upstream signal for EMT regulation |
| HIF1A | Hypoxia-inducible factor; promotes EMT | Central to hypoxia-driven EMT |
| KDM1A | Lysine-specific demethylase 1; epigenetic repressor | Epigenetic regulator of EMT; drug target |
| BRCA1 | DNA repair protein; modulates EMT | Loss is associated with EMT in breast cancer |
| VIM | Vimentin; mesenchymal marker | Readout of EMT in experiments |
| FN1 | Fibronectin; extracellular matrix protein | Mesenchymal marker and EMT effector |
| CDH2 | N-cadherin; mesenchymal adhesion molecule | Marker of EMT and invasion |
| MMP2 | Matrix metalloproteinase; degrades basement membrane | Effector of EMT-associated invasion |
| MMP9 | Matrix metalloproteinase; promotes invasion | Effector of EMT in cancer |
| AKT1 | Kinase in survival and EMT signaling | Modulates EMT downstream of growth factors |
| MAPK1 | Kinase in MAPK pathway; promotes EMT | Signaling node in EMT regulation |
| CTNNB1 | Beta-catenin; Wnt signaling effector | Links Wnt signaling to EMT |
How Is regulation of epithelial to mesenchymal transition Regulated?
Regulation of EMT (GO:0010717) is itself controlled at multiple levels. Upstream, TGF-beta, Wnt, Notch and hypoxia signaling activate EMT transcription factors. Hypoxia stabilizes HIF-1alpha, which promotes EMT-associated gene expression. Epigenetic enzymes such as LSD1/KDM1A modify chromatin to repress epithelial genes and sustain the mesenchymal state. BRCA1 can modulate EMT in breast cancer, linking DNA repair to cell plasticity. MicroRNAs and feedback loops maintain hybrid E/M states, adding another layer of regulation. These mechanisms make EMT a highly dynamic and context-dependent process.
regulation of epithelial to mesenchymal transition and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SNAI1 | Cancer metastasis, fibrosis | Knockout and overexpression in carcinoma cell lines |
| BRCA1 | Breast cancer susceptibility and EMT | Knockout in breast epithelial cells; point mutation of BRCA1 |
| HIF1A | Hypoxia-driven EMT in cancer | Knockout under hypoxia; reporter knock-in |
| KDM1A | Epigenetic regulation of EMT; cancer | Knockout and catalytic-dead point mutation |
| CDH1 | Loss of E-cadherin in cancer | Knockout and knock-in of CDH1 mutations |
Cancer metastasis and chemoresistance
Dysregulated EMT regulation is a major driver of cancer invasion and metastasis. In osteosarcoma, EMT regulation is linked to aggressive behavior and poor outcomes. BRCA1 loss in breast cancer is associated with EMT and increased metastatic potential. Hybrid E/M states in cancer are associated with stemness and resistance to therapy. Targeting EMT regulators is therefore a promising anti-metastatic strategy.
Trophoblast biology and pregnancy disorders
Epigenetic regulation of EMT is essential for trophoblast invasion and placental development. Disruption of these regulatory mechanisms is implicated in pregnancy disorders such as preeclampsia. This highlights that GO:0010717 is not limited to cancer but also governs normal developmental processes.
Fibrosis and tissue remodeling
EMT-like processes contribute to fibrosis in kidney, lung and liver, where epithelial cells acquire mesenchymal features. Regulation of EMT by TGF-beta and epigenetic modifiers is central to fibrotic remodeling. Understanding these mechanisms may lead to anti-fibrotic therapies.
From regulation of epithelial to mesenchymal transition-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is a candidate gene required for EMT? | CRISPR knockout in epithelial cell line followed by TGF-beta treatment |
| Does a specific mutation alter EMT regulation? | Point mutation knock-in of the endogenous locus |
| Does overexpression of an EMT inducer drive transition? | Doxycycline-inducible overexpression of SNAI1 or TWIST1 |
| Where and when is an EMT regulator expressed? | Tagged knock-in with fluorescent or epitope tag |
| Which genes modulate EMT in a genome-wide manner? | CRISPR library screening with EMT reporter |
| How does hypoxia affect EMT regulators? | HIF1A knockout or knock-in under hypoxic conditions |
How to Study the regulation of epithelial to mesenchymal transition Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global transcriptome changes | Identify EMT gene signatures and hybrid states |
| ChIP-seq | Histone modifications and factor binding | Map epigenetic regulation of EMT genes |
| ATAC-seq | Chromatin accessibility | Detect regulatory element changes during EMT |
| Western blot | Protein levels of EMT markers | Validate E-cadherin loss and vimentin gain |
| Immunofluorescence | Protein localization and morphology | Visualize junction disassembly and polarity loss |
| CRISPR knockout screen | Gene requirement for EMT | Discover novel regulators of GO:0010717 |
| CRISPR activation screen | Gene sufficiency to induce EMT | Identify drivers of mesenchymal state |
| Live-cell imaging | Cell migration and junction dynamics | Track EMT in real time |
Transcriptomic profiling
RNA-seq is used to measure global gene expression changes during EMT and to identify epithelial and mesenchymal gene signatures. It can reveal hybrid E/M states by detecting co-expression of both programs. Time-course RNA-seq after EMT induction helps define regulatory cascades.
Epigenomic and chromatin analysis
ChIP-seq for histone modifications and DNA methylation profiling reveal epigenetic changes that accompany EMT regulation. These methods help map how LSD1/KDM1A and other modifiers repress epithelial genes. In trophoblast studies, epigenomic approaches have clarified developmental EMT regulation.
Protein and imaging methods
Western blot and immunofluorescence for E-cadherin, N-cadherin and vimentin are standard readouts of EMT. Live-cell imaging can track junction disassembly and migration in real time. Proximity ligation and co-immunoprecipitation can identify protein complexes involving EMT regulators.
Functional genomics with CRISPR
CRISPR knockout and activation screens with EMT reporters identify positive and negative regulators of GO:0010717. Pooled library screening followed by sequencing quantifies guide enrichment. These approaches are unbiased and scalable for discovery of novel EMT modulators.
How CRISPR Can Be Used to Study GO:0010717 regulation of epithelial to mesenchymal transition
Knockout
CRISPR knockout of candidate EMT regulators such as SNAI1, ZEB1 or KDM1A can test whether they are required for EMT induction. Knockout of BRCA1 in breast epithelial cells has been used to study its role in EMT regulation. Knockout of HIF1A clarifies hypoxia-driven EMT. These models provide causal evidence for GO:0010717 annotations.
Point Mutation
Point mutation knock-in can dissect catalytic versus scaffolding functions of epigenetic enzymes like LSD1/KDM1A. It can also model disease-associated mutations in BRCA1 that affect EMT. Such isogenic models are valuable for precision medicine research.
Knock-in
Tagged knock-in of EMT transcription factors with fluorescent or epitope tags enables live tracking and chromatin immunoprecipitation. Reporter knock-in of CDH1 or VIM can serve as sensitive EMT readouts. Knock-in of patient-derived mutations in CDH1 can model hereditary cancer.
Overexpression
Inducible overexpression of SNAI1, TWIST1 or TGFB1 can drive EMT in otherwise epithelial cells. Overexpression of HIF1A under normoxia can mimic hypoxic EMT. These systems are useful for gain-of-function studies and for testing inhibitors.
How EDITGENE Supports regulation of epithelial to mesenchymal transition Research
Researchers studying regulation of epithelial to mesenchymal transition-related genes often need to determine whether a candidate gene is causally involved in EMT initiation, maintenance or reversal. EDITGENE provides publication-grade CRISPR cell models and screening services to accelerate this causal testing.
Contact EDITGENE today to design your custom CRISPR model for regulation of epithelial to mesenchymal transition research.
Frequently Asked Questions About regulation of epithelial to mesenchymal transition
What is GO:0010717 regulation of epithelial to mesenchymal transition?
GO:0010717 is a Gene Ontology biological process term describing any process that modulates the rate, frequency, or extent of epithelial to mesenchymal transition, in which epithelial cells lose polarity, disassemble junctions, degrade basement membrane and become migratory mesenchymal cells.
What genes are involved in regulation of epithelial to mesenchymal transition?
Key genes include SNAI1, SNAI2, TWIST1, ZEB1, ZEB2, CDH1, TGFB1, HIF1A, KDM1A and BRCA1, among others.
Why is regulation of EMT important in cancer?
Dysregulated EMT regulation promotes invasion, metastasis and therapy resistance, making it a major target for anti-cancer strategies.
What are hybrid E/M states?
Hybrid E/M states are intermediate phenotypes where cells co-express epithelial and mesenchymal markers, often associated with stemness and poor prognosis.
How is EMT regulated epigenetically?
Epigenetic enzymes such as LSD1/KDM1A modify histones and DNA to repress epithelial genes and stabilize the mesenchymal state.
What role does hypoxia play in EMT regulation?
Hypoxia stabilizes HIF-1alpha, which activates EMT-associated gene expression and promotes mesenchymal transition.
How can CRISPR be used to study EMT?
CRISPR knockout, knock-in, point mutation and overexpression models allow causal testing of EMT regulators in isogenic backgrounds.
What methods are used to study regulation of EMT?
Common methods include RNA-seq, ChIP-seq, Western blot, immunofluorescence, live-cell imaging and CRISPR screens.
Is regulation of EMT relevant to pregnancy?
Yes, epigenetic regulation of EMT is important in trophoblast biology and is implicated in pregnancy disorders.
What is the role of BRCA1 in EMT?
BRCA1 modulates EMT in breast cancer, linking DNA repair deficiency to increased mesenchymal phenotype.
Conclusion
GO:0010717 regulation of epithelial to mesenchymal transition is a central biological process that integrates signaling, transcription and epigenetics to control a reversible cell-state change. Its dysregulation contributes to cancer metastasis, fibrosis and trophoblast disorders, making it a high-priority area for functional genomics. CRISPR-based models and screening approaches now enable precise causal interrogation of EMT regulators, accelerating both basic discovery and therapeutic development.
References
- 1. Hinton K et al.. 2023. Regulation of the Epithelial to Mesenchymal Transition in Osteosarcoma.. Biomolecules 13(2) PMID: 36830767
- 2. Choudhury J et al.. 2022. Epigenetic regulation of epithelial to mesenchymal transition: a trophoblast perspective.. Mol Hum Reprod 28(5) PMID: 35451485
- 3. Debnath P et al.. 2022. Epithelial-mesenchymal transition and its transcription factors.. Biosci Rep 42(1) PMID: 34708244
- 4. Sengodan SK et al.. 2018. Regulation of epithelial to mesenchymal transition by BRCA1 in breast cancer.. Crit Rev Oncol Hematol 123:74-82 PMID: 29482782
- 5. Simeone P et al.. 2019. The multiverse nature of epithelial to mesenchymal transition.. Semin Cancer Biol 58:1-10 PMID: 30453041
- 6. Sinha D et al.. 2020. Emerging Concepts of Hybrid Epithelial-to-Mesenchymal Transition in Cancer Progression.. Biomolecules 10(11) PMID: 33207810
- 7. Wang HY et al.. 2022. Regulation of epithelial-to-mesenchymal transition in hypoxia by the HIF-1α network.. FEBS Lett 596(3):338-349 PMID: 34905218
- 8. Ambrosio S et al.. 2017. Epigenetic regulation of epithelial to mesenchymal transition by the Lysine-specific demethylase LSD1/KDM1A.. Biochim Biophys Acta Gene Regul Mech 1860(9):905-910 PMID: 28720390
